The use of the Psychiatric Electroencephalography Evaluation Registry (PEER) to personalize pharmacotherapy

por Iosifescu, Dan V, Neborsky, Robert J, Valuck, Robert J
Publicado 2016

Measuring severe adverse events and medication selection using a “PEER Report” for nonpsychotic patients: a retrospective chart review

por Hoffman, Daniel A, DeBattista, Charles, Valuck, Robert J, Iosifescu, Dan V
Publicado 2012

Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US

por Schumock, Glen T, Gibbons, Robert D, Lee, Todd A, Joo, Min J, Valuck, Robert J, Stayner, Leslie T
Publicado 2011

Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease

por NAIR, KAVITA V., WOLFE, PAMELA, VALUCK, ROBERT J., MCCOLLUM, MARIANNE M., GANTHER, JULIE M., LEWIS, SONYA J.
Publicado 2020

Effects of a 3-Tier Pharmacy Benefit Design on the Prescription Purchasing Behavior of Individuals With Chronic Disease

por Nair, Kavita V., Wolfe, Pamela, Valuck, Robert J., McCollum, Marianne M., Ganther, Julie M., Lewis, Sonja J.
Publicado 2003

Assessing and predicting drug-induced anticholinergic risks: an integrated computational approach

por Xu, Dong, Anderson, Heather D., Tao, Aoxiang, Hannah, Katia L., Linnebur, Sunny A., Valuck, Robert J., Culbertson, Vaughn L.
Publicado 2017

Parent-Reported Symptoms and Medications Used Among Children With Severe Neurological Impairment

por Feinstein, James A., Feudtner, Chris, Blackmer, Allison B., Valuck, Robert J., Fairclough, Diane L., Holstein, Jacqueline, Gregoire, LiseAnne, Samay, Sadaf, Kempe, Allison
Publicado 2020